Pazopanib for the first-line treatment of advanced renal cell carcinoma

Technology appraisal guidance
Reference number: TA215
Published: 23 February 2011
Last updated: 01 August 2013

TA215 Pazopanib for the first-line treatment of renal cell carcinoma: Appendix B - proposal paper presented to the Institute's Guidance Executive

TA215 Pazopanib for the first-line treatment of renal cell carcinoma: Appendix B - proposal paper presented to the Institute's Guidance Executive

TA215 Pazopanib for the first-line treatment of renal cell carcinoma: Appendix B - proposal paper presented to the Institute's Guidance Executive
09 September 2013
(286.52 Kb 23 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 09 September 2013